DNA | Ginkgo Bioworks Holdings, Inc. Stock Overview

(Stock Exchange: NYSE)

Day's Range	6.21 - 6.57
52 Week Range	5.26 - 75.20
Beta	2.52
Implied Volatility	82.17%
IV Rank	23.63%
Day's Volume	998,541
Average Volume	1,419,119
Shares Outstanding	56,910,332
Market Cap	361,949,712
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-04-19

Valuation
Profitability
Growth
Health
P/E Ratio	-0.49
Forward P/E Ratio	-1.04
EPS	-12.89
1YR Price Target	6.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1,218
Country	USA
Website	DNA

Ginkgo Bioworks Holdings Inc is building a platform to enable customers to program cells as easily to program computers. The company's platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals.

DNA's peers: BEAM, BNTX, OCEA, ENVB, HEPA, ELEV, AVRO, CWBR, EDIT, MRNA, NTLA, NVO, RPRX, VRTX, PRME

*Chart delayed

Analyzing fundamentals for DNA we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see DNA Fundamentals page.

Watching at DNA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DNA Technicals page.